XML 14 R10.htm IDEA: XBRL DOCUMENT

Other Current Assets	3 Months Ended
Other Current Assets	Mar. 31, 2020
Other Current Assets
Other Current Assets	4.Other Current Assets As of March 31, 2020, other current assets included prepaid expenses of $0.5 million, comprised primarily of prepayments made for the Company's clinical trials for prexigebersen in AML and BP1002 in lymphoma of $0.4 million and prepaid insurance of $0.1 million. As of December 31, 2019, other current assets included prepaid expenses of $0.8 million, comprised primarily of prepayments made for the Company's clinical trials for prexigebersen in AML and CML of $0.6 million and prepaid insurance of $0.2 million.